Literature DB >> 25192145

Endurance sport and "cardiac injury": a prospective study of recreational ironman athletes.

Roman Leischik1, Norman Spelsberg2.   

Abstract

BACKGROUND: Participation in triathlon competitions has increased in recent years. Many studies have described left or right ventricular injury in endurance athletes. The goal of this study was to examine the right and left ventricular cardiac structures and function and dynamic cardio-pulmonary performance in a large cohort of middle- and long-distance triathletes.
METHODS: 87 triathletes (54 male and 33 female) were examined using spiroergometry and echocardiography. The inclusion criterion was participation in at least one middle- or long distance triathlon.
RESULTS: Male triathletes showed a maximum oxygen absorption of 58.1 ± 8.6 mL/min/kg (female triathletes 52.8 ± 5.7 mL/min/kg), maximum ergometer performance of 347.8 ± 49.9 W (female triathletes 264.5 ± 26.1 W). Left ventricular ejection fraction (EF) was normal (male triathletes EF: 61.9% ± 3%, female triathletes EF: 63.0% ± 2.7%) and systolic right ventricular area change fraction (RV AFC%) showed normal values (males RV AFC%: 33.5% ± 2.2%, females 32.2% ± 2.8%). Doppler indices of diastolic function were normal in both groups. With respect to the echocardiographic readings the left ventricular mass for males and females were 217.7 ± 41.6 g and 145.9 ± 31.3 g, respectively. The relative wall thickness for males was 0.50 ± 0.07, whereas it was 0.47 ± 0.09 for females. The probability of left ventricular mass >220 g increased with higher blood pressure during exercise (OR: 1.027, CI 1.002-1.052, p = 0.034) or with higher training volume (OR: 1.23, CI 1.04-1.47, p = 0.019).
CONCLUSIONS: Right or left ventricular dysfunction could not be found, although the maximal participation in triathlon competitions was 29 years. A left ventricular mass >220 g is more likely to occur with higher arterial pressure during exercise and with a higher training volume.

Entities:  

Mesh:

Year:  2014        PMID: 25192145      PMCID: PMC4199008          DOI: 10.3390/ijerph110909082

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


1. Introduction

The possibility of myocardial damage due to physical activity has been known since ancient times. According to legend, a soldier named Pheidippides (more likely Philippides) dropped dead after running to Athens from the battle at Marathon with the news of victory [1]. A soldier or courier, he is purported to have already run 240 km from Athens to Sparta and back before running a marathon distance to Athens, and the truth about his story is unknown [2]. What is clear, however, is that this death is the first recorded sport-related death. Some papers have reported on common deaths in triathlon competitions [3] and exercise-induced cardiac fatigue in triathlon competitions [4,5] and other endurance disciplines [6,7]. The problem of cardiac injury with endurance sports is a complex issue [7,8,9]. Figure 1 shows some factors that might influence cardiac injury in endurance athletes.
Figure 1

Factors that might influence heart function during endurance sport.

Factors that might influence heart function during endurance sport. Triathlon is an endurance sport, especially when performed in middle- and long-distance formats (e.g., middle/long distance Ironman: a 1.9/3.8 km swim, a 90/180 km bicycle ride and a 21.1/42.2 km run), mainly under aerobic conditions. It is particularly important for triathletes to perform at sub-maximal levels over a long period to avoid reaching a state of exhaustion [10,11]. Amateur athletes typically take 5 to 6.5 h for middle-distance events and 10 to 16 h for long-distance events. Such long periods of stress require that both the amateur and the top athletes be adequately trained and have sufficient aerobic capacity [10]. A number of studies with small cohorts have reported spiroergometric data [12,13,14,15]. Problems regarding the condition of athletes’ hearts have been identified [16]. These problems are mainly known from observations of professional cyclists [17] and elite runners [18]. Regarding the literature about “exercise-induced” cardiac fatigue and “athlete’s heart”, the following questions have to be asked: Are there signs of cardiac “fatigue” when triathletes have trained hard over a period of years? Are there risks for right ventricular or left ventricular dysfunction for amateur athletes? What type of athletes’ hearts or what type of hypertrophy, concentric or eccentric, is found most often in triathletes? Are there signs of reduced physiological performance?

2. Experimental Section

2.1. Participants

Eighty-seven triathletes were examined, including 54 males and 33 females. All triathletes were examined by echocardiography (except three males) and spiroergometry. Triathletes underwent their annual medical check-up or examination for training preparation in 2011/2012, which would have been performed as part of the normal clinical routine. All examinations were performed by Dr. Roman Leischik or Dr. Norman Spelsberg. The participants were invited to participate in the study during their routine check-up or routine training preparation, and announcements in social media and triathlon clubs were also made. Dr. Roman Leischik is the medical supervisor of the Triathlon Club PV-Witten since 2007. This study was prospective in design.

2.2. Methods: Echocardiography and Spiroergometry

A Vivid 7 echocardiograph, produced by General Electric (Fairfield, CT, USA) was used for the examinations. The Ergobike 8I, produced by Daum (Fürth, Germany), and the Metalizer 3B, produced by Cortex (Leipzig, Germany), were used for the spiroergometric examination. To compare the data from elite triathletes with those of non-elite triathletes, both males and females were divided into two groups according to their aerobic capacity (relative VO2/min/kg at the aerobic threshold). The 20 males and 15 females with the highest values were designated as elite. All triathletes were examined in a single day using first echocardiography and then spiroergometry. All examinations were performed in 2011 and 2012 at the Sports Medicine Center, Hagen, Germany. The spiroergometry was performed in the following manner: the stress test was conducted in stages after successful gas and volume calibration at 50 W for 3 min, 100 W for an additional 3 min, after which it increased by another 30 W for 3 minutes. The test ended when the subject was exhausted. The echocardiographic analysis was conducted according to general recommendations [19,20]. The formula recommended by the American Society of Echocardiography (ASE) was used to calculate the muscle mass. EDV and ESV were determined as monoplane by the modified Simpson method. The spiroergometric analyses were conducted according to the literature. VAT was determined as the first non-linear increase in the ventilatory equivalent for oxygen without a simultaneous increase of the ventilatory equivalent for CO2. RCP was determined as a simultaneous non-linear increase of both ventilatory equivalents according to recommendations [21,22]. VO2max was registered as the highest average value of oxygen absorption over 30 seconds. Elite triathletes were identified by their aerobic capacity. The 20 males and 15 females with the best values of relative oxygen uptake (in mL/min/kg) were classified as elite.

2.2.1. Ethics Statement

All athletes gave verbal and written consent to voluntary performance testing and for use of their data in this study. All data were anonymized. Triathletes underwent their annual medical check-up or examination for training preparation in 2011/2012, which would have been performed in any case as it is clinical routine. The study was approved as a doctoral dissertation by the Dissertation Audit Committee of the University Witten/Herdecke. All examinations (echocardiography and spiroergometry) were a part of the routine clinical and diagnostic care for the triathletes. All examinations were performed by two experienced investigators (see chapter methods). This study did not introduce any pharmaceutical interventions or changes in the clinical course of the triathletes.

2.2.2. Statistical Analyses

The entire statistical analysis was designed as follows. Stata/IC 11.2 for Windows was used for data preparation and statistical analysis. The Mann-Whitney U-Test was used to compare the groups. The Kaplan-Meier product limit method and the Cox proportional hazards model were used to estimate the odds ratios for analysis of the relationship between arterial pressure and the probability of a left ventricular muscle mass (LVM) >220 g. All statistical tests were two-sided, with a significance level of 0.05.

3. Results and Discussion

3.1. Participants Characteristics

Anthropometric data and the general cardiac parameters of the participants are listed in Table 1.
Table 1

Anthropometric and structural echocardiographic characteristics of the study population.

ParametersMaleFemaleMann-Whitney U-Test p-value
nMvSdnMvSd
Age (years)5438.111.83334.38.10.137
Weight (kg)5476.88.93361.57.80.001
Size (cm)54182.46.733168.86.40.001
BMI (kg/m²)5423.01.833321.62.280.001
BSA (m²)541.970.14331.700.130.001
%body fat5412.53.63322.84.70.001
Ao512.900.37332.470.240.001
LA512.540.28332.350.250.002
LAV (mL)5129.17.83327.49.30.254
IVS thickness diastolic (cm)511.230.13331.020.170.001
IVS thickness systolic (cm)511.670.18331.440.220.001
PWT diastolic (cm)511.220.14331.020.160.001
PWTs (cm)511.700.17331.480.200.001
Relative wall thickness510.500.07330.470.090.066
LVEDD (cm)514.80.38334.40.320.001
LVESD (cm)513.30.29332.90.270.001
LVM (g)51217.741.633145.931.30.001
LVM (g/m²)51110.521.83385.818.70.001
LVEDV (mL)51138.522.333105.017.80.001
LVESV (mL)5152.79.93338.97.10.001
SV (mL)5185.714.03366.111.30.001
EF (%)5161.93.03363.02.70.292
LVOT VMax (m/s)510.800.13320.860.130.047
MV EMax (m/s)510.530.10330.560.120.091
MV AMax (m/s)510.360.06330.380.090.569
MV E/A Ratio511.480.31331.540.340.407
RV parasternal513.180.13332.400.180.001
RV AFC%5133.52.23332.22.80.005

n = number; Mv = mean value; Sd = standard deviation; BMI = body mass index; BSA = body surface area; Ao = aortic diameter; LA = left atrial diameter in cm; LAV = left atrial end-systolic volume; IVS = interventricular septum; PWT = diastolic posterior wall thickness; PWTs = systolic posterior wall thickness; RWT = relative wall thickness (formula: 2 × PWT/LVEDD); LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter; LVM = left ventricular mass; LVM (g/m2 ) = LVM/BSA; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume; d = diastolic; s = systolic; SV = stroke volume; EF = left ventricular ejection fraction in %; LVOT VMax = left ventricular outflow tract velocity; MV EMax = early (E) mitral velocity; MV AMax = mitral A (atrial) velocity; RV parasternal = RV diameter from parasternal view in cm; RV AFC = right ventricular area fractional change in %.

Male triathletes have significant greater weight, BMI, and BSA than female triathletes, but lower body fat (12% vs. 22.8%). Heart cavities and stroke volume are significant larger, without differences in systolic function (EF) or diastolic function (Doppler parameters). Anthropometric and structural echocardiographic characteristics of the study population. n = number; Mv = mean value; Sd = standard deviation; BMI = body mass index; BSA = body surface area; Ao = aortic diameter; LA = left atrial diameter in cm; LAV = left atrial end-systolic volume; IVS = interventricular septum; PWT = diastolic posterior wall thickness; PWTs = systolic posterior wall thickness; RWT = relative wall thickness (formula: 2 × PWT/LVEDD); LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter; LVM = left ventricular mass; LVM (g/m2 ) = LVM/BSA; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume; d = diastolic; s = systolic; SV = stroke volume; EF = left ventricular ejection fraction in %; LVOT VMax = left ventricular outflow tract velocity; MV EMax = early (E) mitral velocity; MV AMax = mitral A (atrial) velocity; RV parasternal = RV diameter from parasternal view in cm; RV AFC = right ventricular area fractional change in %.

3.1.1. Echocardiography

Myocardial hypertrophy was common and was classified according to Lang et al. [19] (Table 2 and Table 3).
Table 2

Myocardial hypertrophy in male triathletes.

Left VentricleNormalLightModerateStrong
LVEDD51 (100%)000
IVSD3 (5.9%)39 (76.5%)9 (17.6%)0
PWT4 (7.8%)37 (72.5%)10 (19.7%)0
LVM (g/m²)31 (60.8%)11 (21.6%)7 (13.7%)2 (3.9%)
LVEDV *44 (86.3%)4 (7.8%)2 (3.9%)1 (2.0%)

* Reference values according to Lang et al. [19]; LVEDD: left ventricular end-diastolic diameter; IVSD: interventricular septum diastolic thickness; PWT: diastolic posterior wall thickness; LVM (g/m²): Left ventricular mass/BSA; LVEDV: left ventricular end-diastolic volume.

Table 3

Myocardial hypertrophy in female triathletes.

Left VentricleNormalLightModerateStrong
LVEDD33 (100%)000
IVSD12 (36.4%)18 (54.5%)3 (9.1%)0
PWT12 (36.4%)18 (54.5%)3 (9.1%)0
LVM (g/m²)26 (78.8%)4 (12.1%)1 (3.0%)2 (6.1%)
LVEDV *18 (54.5%)5 (15.2%)8 (24.2%)2 (6.1%)

* Reference values according to Lang et al. [19]; LVEDD: left ventricular end-diastolic diameter; IVSD: interventricular septum-end-diastolic thickness; PWT: diastolic posterior wall thickness; LVM (g/m²): Left ventricular mass/BSA; LVEDV: left ventricular end-diastolic volume.

Myocardial hypertrophy in male triathletes. * Reference values according to Lang et al. [19]; LVEDD: left ventricular end-diastolic diameter; IVSD: interventricular septum diastolic thickness; PWT: diastolic posterior wall thickness; LVM (g/m²): Left ventricular mass/BSA; LVEDV: left ventricular end-diastolic volume. Myocardial hypertrophy in female triathletes. * Reference values according to Lang et al. [19]; LVEDD: left ventricular end-diastolic diameter; IVSD: interventricular septum-end-diastolic thickness; PWT: diastolic posterior wall thickness; LVM (g/m²): Left ventricular mass/BSA; LVEDV: left ventricular end-diastolic volume. In the study population, concentric changes of the left ventricle characterized the echocardiographic morphological picture. Concentric remodeling for males was found in 26 cases and concentric hypertrophy was observed in 21 cases. One male triathlete had eccentric hypertrophy, and three had normal myocardial anatomy. Seventeen females displayed concentric remodeling, and 6 females had concentric hypertrophy. Cardiac adaptation forms are visualized in Table 4.
Table 4

Cardiac adaptation in the study collective *.

RWT >0.42 cmConcentric RemodelingConcentric Hypertrophy
Males: 26Males: 21
Females: 17Females: 6
RWT <0.42 cmNormalEccentric Hypertrophy
Males: 3Males: 1
Females: 9Females: 1

* Reference values and definition according to Lang et al. [19]; RWT: relative wall thickness (formula: 2 × PWT/LVEDD).

Cardiac adaptation in the study collective *. * Reference values and definition according to Lang et al. [19]; RWT: relative wall thickness (formula: 2 × PWT/LVEDD). The classification into types of hypertrophy followed the criteria of Lang et al. [19]. Right ventricular remodeling or other pathological findings in the right ventricle were not found. Left ventricular function was excellent in all triathletes, even if they trained hard and had finished middle- or long-distance triathlons.

3.1.2. Spiroergometry/Physiological Performance

Oxygen absorption, ergometer performance and heart rate with VAT, RCP and at peak capacity are shown in Table 5 (males) and Table 6 (females).
Table 5

Males: heart rate, oxygen uptake and power output according to performance.

MeasurementsElite MalesNon-Elite Malesp-Value *
nMvSdnMvSd
AT (aerobic threshold)
HR20160.49.134144.913.00.000
aVO2203.850.46343.140.520.000
rVO22053.15.23439.85.50.000
%VO2max2082.46.63473.911.70.004
Watt20314.547.034259.744.10.000
RCP (respiratory compensatory point, anaerobic threshold)
HR20170.87.434157.712.20.000
aVO2204.370.61343.590.480.000
rVO22060.16.63445.45.10.000
%VO2max2092.36.93484.410.40.003
Watt20346.348.634289.738.20.000
Peak capacity
HR20180.47.134144.913.00.000
aVO2max204.70.7344.30.60.060
rVO2max2064.76.73454.27.10.000
Wattmax20367.047.634336.548.30.026

n = number; Mv = mean value; Sd = standard deviation; aVO2 = absolute VO2max in L/min; rVO2 = relative VO2 in mL/kg−1·min−1; * = of the Mann-Whitney U-Test; HR = heart rate; Watt = power output.

Table 6

Females: heart rate, oxygen uptake and power output according to performance.

MeasurementsElite FemalesNon-Elite Femalesp-Value *
nMvSdnMvSd
VAT (ventilatory aerobic threshold)
HR15160.614.518138.619.90.002
aVO2152.760.35181.990.460.001
rVO21545.55.41832.73.80.001
%VO21581.27.01864.412.90.001
Watt15230.024.518162.241.40.001
RCP (respiratory compensation point, anaerobic threshold)
HR15169.812.618152.321.00.016
aVO2153.060.28182.330.560.001
rVO21546.814.91837.46.30.001
%VO2max1591.76.71875.314.70.001
Watt15252.523.818195.044.00.001
Peak capacity
HR15179.710.018179.87.60.971
aVO2max153.40.3183.10.30.006
rVO2max1556.15.71850.14.10.004
Wattmax15274.032.518256.716.40.097

n = number; Mv = mean value; Sd = standard deviation; aVO2 = absolute oxygen uptake in L/min; rVO2 = relative oxygen uptake in mL/kg−1·min-1; * = Mann-Whitney U-Test; HR = heart rate; Watt = power output; max = maximum.

Males: heart rate, oxygen uptake and power output according to performance. n = number; Mv = mean value; Sd = standard deviation; aVO2 = absolute VO2max in L/min; rVO2 = relative VO2 in mL/kg−1·min−1; * = of the Mann-Whitney U-Test; HR = heart rate; Watt = power output. Females: heart rate, oxygen uptake and power output according to performance. n = number; Mv = mean value; Sd = standard deviation; aVO2 = absolute oxygen uptake in L/min; rVO2 = relative oxygen uptake in mL/kg−1·min-1; * = Mann-Whitney U-Test; HR = heart rate; Watt = power output; max = maximum.

3.1.3. Left Ventricular Hypertrophy

According to the values reported by Devereux et al. [23] and Bove et al. [24], we divided male triathletes into two groups, group 1 with LVM >220 g and group 2 with LVM <220 g, to assess the possible reasons for left ventricular hypertrophy. The significant differences between the two groups are visible in Table 7.
Table 7

Differences between males with LV-mass >220 g and <220 g.

LV Mass (ASE) gMale < 220 gMales > 220 gp-Value
nMvSdnMvSdMann-Whitney U-Test
VO2AT273.20.5243.70.50.001
Training distance bike27190.365.824250.2600.004
SV (Teich) mL276311.72472.913.30.006
SV index (Teich) mL/m²2732.25.923366.30.018
Left atrium (cm)272.460.27242.640.270.020
WattsAT27265.646.624301.353.40.023
Training time bike2772.2248.62.40.034
Training time (overall)2715.72.72417.83.30.035
Wattmax27336.741.924363.856.60.042
Training time swimming273.21.2243.81.40.049
RRsWattmax27188.120.424199.619.90.055
RRsAT2717824.624192.920.50.056
VO2max274.30.5244.60.80.059

VO2AT: oxygen uptake at the aerobic threshold (VAT) in L/min; Training-distance bike: kilometers/week; SV (Teichholz) mL: left ventricular stroke volume; Training time bike: hours/week Training time overall: hours/week Wattmax: maximal power; Training time swimming: hours/week; RRsWattmax: systolic arterial pressure during maximal exercise; RRsAT: systolic arterial pressure at the aerobic threshold; VO2max: maximal oxygen uptake in L/min.

Differences between males with LV-mass >220 g and <220 g. VO2AT: oxygen uptake at the aerobic threshold (VAT) in L/min; Training-distance bike: kilometers/week; SV (Teichholz) mL: left ventricular stroke volume; Training time bike: hours/week Training time overall: hours/week Wattmax: maximal power; Training time swimming: hours/week; RRsWattmax: systolic arterial pressure during maximal exercise; RRsAT: systolic arterial pressure at the aerobic threshold; VO2max: maximal oxygen uptake in L/min. Additional results about the possible reasons for LV hypertrophy were calculated by odds ratios (Table 8).
Table 8

Probability of LVM >220 g: odds ratios.

ParametersLVMOR95%-CIp-Value
<220 g (n = 27)>220 g (n = 24)
MvSDMvSD
BPsRest125.410.8130.815.71.0310.9891.0740.148
BPs Aero.thresh.178.024.6192.920.51.0271.0031.0510.025
BPs Anae.thresh.185.221.5198.822.31.0271.0021.0520.034
BPsWmax188.120.4199.619.91.0271.0001.0540.050
Tr.time swim3.21.23.81.41.460.952.250.081
Tr.time bike7.02.28.62.41.331.061.660.015
Tr.time run4.91.54.91.21.050.701.560.823
Training time15.72.717.83.31.231.041.470.019
Triathlon since y14.59.015.710.31.010.961.070.654

BPs = systolic blood pressure (mmHg); Tr.time = training time in hours/week; Aero.thresh. = aerobic threshold; Anae.thresh. = anaerobic threshold; y = years.

Probability of LVM >220 g: odds ratios. BPs = systolic blood pressure (mmHg); Tr.time = training time in hours/week; Aero.thresh. = aerobic threshold; Anae.thresh. = anaerobic threshold; y = years. With respect to the relationship between arterial hypertension and myocardial hypertrophy, 32 male triathletes had a wall thickness >1.2 cm, whereas 19 had a thickness <1.2 cm. In these male athletes, the mean arterial blood pressure values of 196.9 mmHg and 187.9 mmHg (p = 0.075) were measured at the maximal watts level (Wmax). The odds ratios showed a significant relationship between the arterial pressure values during exercise (at the aerobic and anaerobic threshold). There was an additional relationship between the overall training time and a LVM >220 g (Table 8).

3.1.4. Training Habits/History

The mean training times were similar in male and female triathletes (Table 9). The mean time for swimming was 3.5 h/week, for biking 6–8 h a week, for running 5 h a week. Total training time was 14–15 h/week. The maximal training time for triathlon was 29 years for a 64 years old male triathlete. The oldest female triathlete was 45 years old and had trained for triathlons for 5 years. Four athletes had a history of Chlamydia pneumoniae infections.
Table 9

Training habits/week.

TrainingsMalesFemalesTimes/distances
nMvSdnMvSd
Swimming543.51.28333.61.19hours
547.83.9337.53.5km
Biking547.82.39336.62.05hours
54218.668.933168.570.9km
Running544.91.36335.11.36hours
5452.413.33351.514km
Tr.time/week5416.73.13315.53.3hours
Triathlon years549.06.4336.44.5years
Sport years5414.99.43313.76.8years

Mv = mean value; Sd = standard deviation.

Training habits/week. Mv = mean value; Sd = standard deviation.

3.2. Discussion

Sports-related cardiac injury is a very broadly discussed issue [7,8,9]. The most substantial cardiac injury is sport-related sudden death. Most cases of sudden death in athletes over 35 years of age are caused by coronary disease [25], and their prognoses depend on the coronary arteriosclerosis burden [26] rather than on a possible increase in biomarkers during competition. The sudden deaths of young athletes <35 years (Table 10) typically have different causes (hypertrophic cardiomyopathy, coronary disease, coronary anomalies, myocarditis and arrhythmogenic right ventricle) [27,28,29,30].
Table 10

Causes of sudden cardiac death in young athletes 12–35 years old (percentages).

Causes of cardiac sudden deathMaron [27]Corrado [29]Solberg [30]Marijon [28]
Aortic rupture2.21.84.32
Aortic stenosis/cong. HD1.8 4.36
ARVC422 4
Channelopathies (QT, WPW)31.88.712
Coronary artery anomalies24113.3
Coronary disease318486
Dilatative CM21.8 4
Hypertrophic CM361.84.310
MVP47.3 2
Myocarditis5.49224
Possible HCM11.3 4
Riva muscle bridge2.23.6 2
Unclear 1.8 36
n = 1049n = 55n = 22n = 50

cong. HD = congenital heart disease; ARVC = arrhythmogenic right ventricular cardiomyopathy; QT = QT-syndrome (including Romano-Ward syndrome and Jervell-Lange-Nielsen syndrome); WPW = Wolff-Parkinson-White syndrome; CM = cardiomyopathy; HCM = hypertrophic cardiomyopathy; MVP = mitral valve prolapsed.

In this study, pathological structural cardiac changes could not be observed. The dynamic physiological performance of the triathletes showed high baseline values without functional signs of cardio-pulmonary impairment. Causes of sudden cardiac death in young athletes 12–35 years old (percentages). cong. HD = congenital heart disease; ARVC = arrhythmogenic right ventricular cardiomyopathy; QT = QT-syndrome (including Romano-Ward syndrome and Jervell-Lange-Nielsen syndrome); WPW = Wolff-Parkinson-White syndrome; CM = cardiomyopathy; HCM = hypertrophic cardiomyopathy; MVP = mitral valve prolapsed.

3.2.1. Cardiac Adaptation to Exercise and Left Ventricular Hypertrophy

The specific endurance training of triathletes leads to physiological changes in their performance parameters [31] and results in changes in cardiac function or cardiac structures [32]. This adaptation is linked to the nature and magnitude of the physical exercise [16,33]. The physiological adaptation is a “harmonic increase in [the] size” of a healthy heart caused by physical activity [34]. The term “athlete’s heart” [16] has been used since 1899 [35]. The sudden death of athletes is more often a problem for male athletes [28]. Different causes of sudden death [27], (silent coronary disease [30], hypertrophic cardiomyopathy [27] and arrhythmogenic right ventricular cardiomyopathy [29]) have been reported. Cardiovascular adaptations to exercise have been systematically defined and differ according to the type of conditioning endurance training [33,36,37]. Cycling and rowing have the biggest effects on the cavity size and wall thickness [27,38]. Concentric hypertrophy in triathletes has already been described [39]. Douglas et al. [40] suggested that athletes developed hypertrophy from the systolic blood pressure increase during exercise, which could be explained by the frequency of the training. The diastolic function was normal under these conditions. In the present study, odds ratio analysis showed a relationship between myocardial thickening and exercise arterial pressure. Intense, long-term training with exercise-induced blood pressure elevation can lead to hypertrophy that mimics the conditions of pathological arterial pressure changes. The male triathletes with a wall thickness >1.2 cm had higher arterial pressure (196.9 mmHg vs. 187.9 mmHg; p = 0.075) at the peak capacity (maximum wattage), but this difference was not significant. This difference was found only in males; the average arterial pressure values for females were not different and did not increase. Indicators of an increase in wall thickness additional other than dilatation have been confirmed in a study of female athletes [41] that compared long-distance and short-distance runners. Endurance training for females causes an increase in the wall thickness rather than the dilatation of the left ventricle. However, the RWT reported in that study is significantly lower than what we observed (0.384 ± 0.052). The basic assumption for triathletes that this sport can lead to eccentric rather than to concentric hypertrophy was not confirmed in this study. There were signs of remodeling with primarily concentric hypertrophy in the female subjects in the present study. Concentric remodeling for males was found in 26 cases, and concentric hypertrophy could be observed in 21 cases. Concentric remodeling and concentric hypertrophy are more common in male athletes [16]. Different authors have concluded that strength training predominantly leads to concentric hypertrophy and endurance training leads to eccentric hypertrophy [42]. In this study, concentric remodeling was the most frequently observed. George et al. [16] reported that the expected pattern of eccentric enlargement was replaced by a pattern of concentric or symmetric enlargement in groups of highly trained athletes. Generally, the adaptation of the cardiac mass does not appear to depend on the type of conditioning [16]. In our opinion, the results of wall thickness measurements depend on the cohort size, age and gender. In 1989, Douglas et al. [43] published a comparison of 36 triathletes comprising 17 normal control and 15 high-pressure subjects. The authors reported that the triathletes underwent cardiac adaptations similar to pressure overload of the left ventricle and described an RWT of 0.41. In these triathletes, the left ventricular muscle mass was positively correlated with the systolic blood pressure during exercise. The difference between triathletes and cycle racers is that the training not only takes place under strength/endurance conditions, as during a cycle race, but it also occurs under running conditions. Modified strength training also results in different changes in the cardiac structures of triathletes compared to professional cycle racers [44]. In a study of 14 professional cycle racers, the authors found that the left ventricular muscle mass as well as the diastolic cardiac parameters resulted in eccentric hypertrophy more than concentric hypertrophy, which contrasts with our study. The functional changes of the cardiac structures for triathletes resemble the changes in runners [45].

3.2.2. Right or Left Ventricular “Fatigue”

Some papers have reported that excessive endurance training may cause negative remodeling of cardiac structures [9,46,47]. Predominantly, ultra-marathons and Ironman-distance triathlons can cause transient overload of the right ventricle [46,47,48]. Fibrosis of the left ventricle in older runners is a possible cause of death [49,50]. Diverse patterns of myocardial fibrosis were reported by Wilson et al. [50]. Heidbüchel [51] postulates that load-induced, right ventricular arrhythmogenic cardiomyopathy could lead from repetitive microtrauma to chronic and structural changes of the right ventricle and “pro-arrhythmogenesis”. In his view, ventricular tachycardia originating from the right ventricle is responsible for the acute deaths. His hypothesis is based on a retrospective analysis of electrophysiological examinations in 2003 [52]. The discussion concerning cardiac injury and endurance sports is ongoing [7,8,9,53]. Pelliccia et al. [54] examined the left ventricular function of 114 Olympic athletes in a long-term follow-up study. The global left systolic function was unchanged, and wall motion abnormalities were absent. D’Andrea et al. [55] examined the right ventricle function in 650 top-level athletes and found enlarged right ventricular and right atrial dimensions; they described this as a “physiologic phenomenon.” Additionally, long-term-training marathon runners did not suffer any long term injury of the right ventricle (including examination by advanced strain technology) [56]. The systolic function of the left ventricle was not negatively influenced in our study cohort. The right ventricular fractional area change was normal in all triathletes. The oldest triathlete in our study had competed in triathlons for 29 years. The diastolic function in our cohort was not materially impaired. The E/A ratio, however, was slightly lower, as reported by Douglas et al. [40]. The impact of exercise-induced arterial hypertension (EIAH) is known in healthy subjects [57]. There is strong evidence that athletes have a higher incidence of atrial fibrillation [58,59] and bradyarrhythmias with increasing age [58,60]. We do not know the definitive reasons for this (increased atrial pressure?), but EIAH and LVM can cause atrial fibrillation in endurance athletes. The general prevalence or incidence of EIAH in athletes is unknown. The problem of EIAH seems to occur more in male competitive athletes who undergo a vigorous training schedule [57]. Low-intensity training and aerobic exercise have been shown to help decrease blood pressure [61,62]. The hypertensive or non-hypertensive response to exercise seems to be related to hereditary factors [63], to aging or to the individual arterial stiffness [64]. It is crucial to define the people who are at risk and to start therapy if possible [65]. In our daily practice, we treat subjects with low-dose ACE inhibitors or AT1-blockers before training or competition. The dosage should be tested using an exercise test. The present study shows the relationship between EIAH and cardiac hypertrophy (Table 5).

3.2.3. Dynamic Physiological Performance

A prerequisite of successful participation in middle- and long-distance triathlons is sufficient aerobic capacity [31]. It also appears that this is essential for avoiding possible damage due to long-term endurance training [4]. In the present study, 54 male athletes had a VO2max of 58.1 mL/kg−1·min−1 and a VAT of 44.7 mL/kg−1·min−1. These data are in agreement with published data from smaller studies. The VO2 for the VAT was between 34 and 49 mL/kg−1·min−1 body weight in previously published studies, which depends on the subject group. The maximum oxygen absorption in the previously published studies had a range of 43 to 74 mL/kg−1·min−1 body weight among the different groups that were examined. In contrast, studies of groups with, for example, five world-class athletes [66] report higher results. However, it can be postulated that a VO2max >55 mL/kg−1·min−1 body weight is a good marker for successful participation in an Ironman competition at both middle and long distances. The oxygen absorption at the aerobic threshold should be >45 mL/min/kg body weight for males and >35 mL/kg−1·min−1 body weight for females. In the present study, the examinations always took place using egometric peak capacity by bicycle; treadmill data can differ depending on the athletes’ background [13]. Bunc et al. [67] propose the use of VO2max values for young Olympic triathletes, with males having an average of >65 mL/min/kg and females >60 mL/min/kg. This pertains to elite triathletes. In smaller studies using bicycle ergometry, the maximum oxygen absorption values for female athletes (e.g., [68]) averaged 57.5 mL/kg−1·min−1 body weight, and the average oxygen absorption value for ten Olympic-level female athletes [69] was at VAT of 37.7 mL/min/kg body weight. The overall male and female group examined here had a physiological profile that matches well-trained and ambitious triathletes, though it does not compare to the equivalent values for world-class athletes. When comparing the performance values of elite and non-elite male athletes (Table 2) in the present study, a significant difference was observed, as expected (relVO2max for males 64 ± 6.7 vs. 54.9 ± 6.7 mL/kg−1·min−1 and VO2 for VAT 53.1 ± vs. 39.8 ± 5.5 mL/kg−1·min−1). A similar difference in the range of VO2max was observed for female athletes (Table 3). In summary, the results from this study show a difference in VO2max, which is not as high as observed in triathletes examined in other studies. The values determined for German elite and amateur athletes are within the range of internationally determined parameters.

3.2.4. Study Limitations and Future Directions

The cross-sectional design of this study did not allow us to exclude the possibility of negative effects of endurance sport in the triathletes, although our data suggest that our examined triathletes had no significant signs of cardiac injury except for the signs of the hypertrophy. The pathological relevance of the athletes’ hypertrophy is under discussion. Confirmatory longitudinal studies are necessary. It is not possible to exclude, that using of strain or tissue Doppler technique might provide diagnosis of abnormal cardiac function. Biplane analysis of the ventricular volumes might provide small changes in the stroke volume analysis, but in participants without regional wall motion abnormalities or cardiac infarction they are negligible.

4. Conclusions

The data of the present study on German triathletes participating in the middle- and long-distance events allow for the practical use of this information as a routine part of sports medicine in classifying the efficiency of performance diagnostic centers. In males, the training goals aim for an aerobic capacity of VAT = 45 mL/kg−1·min−1, (males) or 35 mL/kg−1·min−1 (females). In terms of the echocardiographic measurement, we can expect concentric remodeling/concentric hypertrophy. Valve dysfunctions are possible but rare. Accordingly, the blood pressure values should be thoroughly examined during routine or pre-event check-up. We conclude that the relationship between myocardial thickening and arterial blood pressure during exercise remains an open issue. With respect to echocardiography, we did not observe cardiac dysfunction in our athletes. The idea of exercise-induced cardiac disease was suggested by Heidbüchel [51] and LaGerche [46] but the data are controversial [8,53]. In our cohort, with the mean time of participation in triathlon competitions of 9.0 years in males and 6.4 years in females (Table 9, we did not find the negative long-term effects on cardiac structures that had been proposed for exercised-induced cardiac fatigue. The longest time for participating in triathlon competitions was 29 years (one 64-year-old triathlete, with Ironman-distance times of ca. 11 h). There is no doubt that athletes have a higher incidence of atrial fibrillation [58] and bradyarrhythmias [60]. Elite athletes (particularly men) have improved longevity because of the rare occurrence of cardiovascular disease [70]. Early death in individuals due by myocardial fibrosis is possible [49]. The general incidence of exercise-induced cardiac injury is not known, and the dose of exercise bouts and individual sensitivity has yet to be defined and should be evaluated in further prospective studies [71]. In all athletes with suspicious inflammation/myocarditis or in cases of power/performance lost, blood tests must be performed, especially for Chlamydia pneumoniae [72] or other bacterial/viral infections. The impact of exercise-induced arterial hypertension in endurance athletes remains an open issue [57]. Abnormal exercise-induced cardiac hypertrophy might be a risk factor for arrhythmia [57]. Further prospective studies on possible cardiac “negative remodeling” due to participation in sports (exercise-induced cardiac fatigue) with larger cohorts and under clearly defined conditions should be conducted. In addition, the optimal training volume of physical activity concerning the general survival rate should be investigated prospectively. Considering the dominant probability of coronary heart disease in ambitious athletes >35 years, risk stratification with exercise-tests/imaging techniques [73,74] is advisable in addition to basic examination (medical history/physical examination/12-channel-ECG). Marijon et al. [28] reported a five-fold higher cardiac mortality in young, ambitious competitive athletes (relative risk 9.8, 95%, CI 3.7 to 16) than in non-competitive athletes (2.2, 95%, CI 1.4 to 3.0). This fact supports the need for a more detailed examination of athletes <35 years and to identify people who are at risk. Given the value of competitive sporting activities to hobby-athletes, the media, and other industries, physical activity in the general population is of fundamental importance [75]. Further prospective examinations and studies about the long-term adverse effects of endurance sports should be performed.
  69 in total

1.  Sudden death during the triathlon.

Authors:  Kevin M Harris; Jason T Henry; Eric Rohman; Tammy S Haas; Barry J Maron
Journal:  JAMA       Date:  2010-04-07       Impact factor: 56.272

2.  Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Authors:  Barry J Maron; Paul D Thompson; Michael J Ackerman; Gary Balady; Stuart Berger; David Cohen; Robert Dimeff; Pamela S Douglas; David W Glover; Adolph M Hutter; Michael D Krauss; Martin S Maron; Matthew J Mitten; William O Roberts; James C Puffer
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

3.  Post-mortem evidence of idiopathic left ventricular hypertrophy and idiopathic interstitial myocardial fibrosis: is exercise the cause?

Authors:  G Whyte; M Sheppard; K George; R Shave; M Wilson; S Prasad; R O'Hanlon; S Sharma
Journal:  Br J Sports Med       Date:  2007-08-24       Impact factor: 13.800

4.  Coronary atherosclerosis burden, but not transient troponin elevation, predicts long-term outcome in recreational marathon runners.

Authors:  Stefan Möhlenkamp; Kirsten Leineweber; Nils Lehmann; Siegmund Braun; Ulla Roggenbuck; Mareike Perrey; Martina Broecker-Preuss; Thomas Budde; Martin Halle; Klaus Mann; Karl-Heinz Jöckel; Raimund Erbel; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2013-11-19       Impact factor: 17.165

5.  Sports-related sudden death in the general population.

Authors:  Eloi Marijon; Muriel Tafflet; David S Celermajer; Florence Dumas; Marie-Cécile Perier; Hazrije Mustafic; Jean-François Toussaint; Michel Desnos; Michel Rieu; Nordine Benameur; Jean-Yves Le Heuzey; Jean-Philippe Empana; Xavier Jouven
Journal:  Circulation       Date:  2011-07-25       Impact factor: 29.690

6.  Left ventricular hypertrophy in athletes.

Authors:  P S Douglas; M L O'Toole; S E Katz; G S Ginsburg; W D Hiller; R H Laird
Journal:  Am J Cardiol       Date:  1997-11-15       Impact factor: 2.778

Review 7.  Competitive sports and the heart: benefit or risk?

Authors:  Jürgen Scharhag; Herbert Löllgen; Wilfried Kindermann
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

8.  Long-term clinical consequences of intense, uninterrupted endurance training in olympic athletes.

Authors:  Antonio Pelliccia; Norimitsu Kinoshita; Cataldo Pisicchio; Filippo Quattrini; Fernando M Dipaolo; Roberto Ciardo; Barbara Di Giacinto; Emanuele Guerra; Elvira De Blasiis; Maurizio Casasco; Franco Culasso; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2010-04-13       Impact factor: 24.094

9.  Cardiac considerations in the triathlete.

Authors:  P S Douglas
Journal:  Med Sci Sports Exerc       Date:  1989-10       Impact factor: 5.411

10.  Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study.

Authors:  Kasper Andersen; Bahman Farahmand; Anders Ahlbom; Claes Held; Sverker Ljunghall; Karl Michaëlsson; Johan Sundström
Journal:  Eur Heart J       Date:  2013-06-11       Impact factor: 29.983

View more
  9 in total

1.  Aerobic Capacity, Physical Activity and Metabolic Risk Factors in Firefighters Compared with Police Officers and Sedentary Clerks.

Authors:  Roman Leischik; Peter Foshag; Markus Strauß; Henning Littwitz; Pankaj Garg; Birgit Dworrak; Marc Horlitz
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

Review 2.  Pre-participation and follow-up screening of athletes for endurance sport.

Authors:  Roman Leischik; Birgit Dworrak; Peter Foshag; Markus Strauss; Norman Spelsberg; Henning Littwitz; Marc Horlitz
Journal:  J Clin Med Res       Date:  2015-04-08

3.  Blood biomarkers in male and female participants after an Ironman-distance triathlon.

Authors:  Tom Danielsson; Jörg Carlsson; Hendrik Schreyer; Jonas Ahnesjö; Lasse Ten Siethoff; Thony Ragnarsson; Åsa Tugetam; Patrick Bergman
Journal:  PLoS One       Date:  2017-06-13       Impact factor: 3.240

4.  Core Temperature Response During the Marathon Portion of the Ironman World Championship (Kona-Hawaii).

Authors:  Guillermo Olcina; Carmen Crespo; Rafael Timón; Jeffrey M Mjaanes; Julio Calleja-González
Journal:  Front Physiol       Date:  2019-12-03       Impact factor: 4.566

5.  Cardiac structure and function in elite female athletes: A systematic review and meta-analysis.

Authors:  Robyn Bryde; Andres I Applewhite; Abd Moain Abu Dabrh; Bryan J Taylor; Michael G Heckman; Sara E Filmalter; George Pujalte; Carlos Rojas; Alexander J Heckman; Tara J Brigham; Larry J Prokop; Brian P Shapiro
Journal:  Physiol Rep       Date:  2021-12

6.  Effect of regular endurance exercises on management of cardiovascular health in middle-aged men.

Authors:  Bo-Ae Lee; Young-Joo Kim
Journal:  J Exerc Rehabil       Date:  2022-02-24

Review 7.  Echocardiography in the evaluation of athletes.

Authors:  Gonzalo Grazioli; Maria Sanz; Silvia Montserrat; Bàrbara Vidal; Marta Sitges
Journal:  F1000Res       Date:  2015-06-15

Review 8.  Variables that influence Ironman triathlon performance - what changed in the last 35 years?

Authors:  Beat Knechtle; Raphael Knechtle; Michael Stiefel; Matthias Alexander Zingg; Thomas Rosemann; Christoph Alexander Rüst
Journal:  Open Access J Sports Med       Date:  2015-08-25

9.  Exercise capacity, cardiovascular and metabolic risk of the sample of German police officers in a descriptive international comparison.

Authors:  Markus Strauss; Peter Foshag; Ulrich Jehn; Richard Vollenberg; Anna Brzęk; Roman Leischik
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.